<html>
  <head>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on May 8, 2024</div>
  </div>
  <div><br>
  </div>
  <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div>
        <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
        <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
        <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
        <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
        <div style="text-align: center; font-weight: bold;">UNDER</div>
        <div style="text-align: center; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
        <div style="text-align: center; font-size: 24pt; font-weight: bold;">Bionano Genomics, Inc.</div>
      </div>
      <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z2b032fa9feb84eb3872f167b8790d99d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">Delaware</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">26-1756290</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of</div>
              <div style="text-align: center; font-weight: bold;">incorporation or organization)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(I.R.S. Employer</div>
              <div style="text-align: center; font-weight: bold;">Identification No.)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 49%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
              <div style="text-align: center; font-weight: bold;">San Diego, California</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">92121</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended</div>
      <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan</div>
      <div style="text-align: center; font-weight: bold;">(Full titles of the plans)</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
      <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
      <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc.</div>
      <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
      <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
      <div style="text-align: center; font-weight: bold;">(858) 888-7600</div>
      <div style="text-align: center; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">Copies to:</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z2a22ed3916754dc2965ee0378de86143" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">Thomas A. Coll, Esq.</div>
              <div style="text-align: center; font-weight: bold;">Su Lian Lu, Esq.</div>
              <div style="text-align: center; font-weight: bold;">Cooley LLP</div>
              <div style="text-align: center; font-weight: bold;">10265 Science Center Drive</div>
              <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
              <div style="text-align: center; font-weight: bold;">(858) 550-6000</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
              <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
              <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc.</div>
              <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
              <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
              <div style="text-align: center; font-weight: bold;">(858) 888-7600</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large
        accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb6e2c3ffa45840cea2e341b4a213e90b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 43.04%; vertical-align: top;">
              <div>Large accelerated filer</div>
            </td>
            <td style="width: 6.95%; vertical-align: top;">
              <div>&#9744;</div>
            </td>
            <td style="width: 43.04%; vertical-align: top;">
              <div>Accelerated filer</div>
            </td>
            <td style="width: 6.95%; vertical-align: top;">
              <div>&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 43.04%; vertical-align: top;">
              <div>Non-accelerated filer</div>
            </td>
            <td style="width: 6.95%; vertical-align: top;">
              <div>&#9746;</div>
            </td>
            <td style="width: 43.04%; vertical-align: top;">
              <div>Smaller reporting company</div>
            </td>
            <td style="width: 6.95%; vertical-align: top;">
              <div>&#9746;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 43.04%; vertical-align: top;">
              <div>Emerging growth company</div>
            </td>
            <td style="width: 6.95%; vertical-align: top;">
              <div>&#9744;</div>
            </td>
            <td style="width: 43.04%; vertical-align: top;">&#160;</td>
            <td style="width: 6.95%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act. &#9744;</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXPLANATORY NOTE</div>
      <div><br>
      </div>
      <div style="text-align: justify;">This Registration Statement on Form S-8 is being filed by Bionano Genomics, Inc. (the &#8220;<font style="font-weight: bold; font-style: italic;">Registrant</font>&#8221;) with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">SEC</font>&#8221;) for the purpose of registering (i) an additional 2,287,580 shares of Registrant&#8217;s Common Stock, par value $0.0001 per share (&#8220;<font style="font-weight: bold; font-style: italic;">Common
          Stock</font>&#8221;), issuable under the Registrant&#8217;s 2018 Equity Incentive Plan, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">2018 Plan</font>&#8221;), pursuant to the provisions of the 2018 Plan providing for an automatic increase
        on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan, and (ii) 22,000 additional shares of Common Stock issuable under the Registrant&#8217;s 2018 Employee Stock Purchase Plan (the &#8220;<font style="font-weight: bold; font-style: italic;">2018 ESPP</font>&#8221;) pursuant to the provisions of the 2018 ESPP providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for
        issuance under the 2018 ESPP.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">PART II</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-right: 6.7pt; margin-left: 4.8pt; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
      <div>&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zea2eb355fc70491abcb71acb8ce0be12" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-weight: bold;">Item 3.</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="margin-left: 5pt; font-weight: bold;">Incorporation of Documents by Reference.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;">These additional shares of Common Stock are securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the 2018 Plan and the 2018 ESPP are effective.
        The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 as noted below.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The following documents filed by the Registrant with the SEC<font style="font-weight: bold; font-style: italic;">&#160;</font>are incorporated by reference into this Registration Statement:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd6d0e507e033427aa5b60b1e51afd824" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The contents of the earlier registration statements on Form S-8 filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702ds8.htm">August 28, 2018</a> (File No. 333-227073), <a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312519091060/d626460ds8.htm">March 29, 2019</a> (File No. 333-230589), <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120005371/nt10009730x2_s8.htm">March 11,
                  2020</a> (File No. 333-237069), <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_s8.htm">August 14, 2020</a> (File No. 333-245764), <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036121009780/nt10022040x2_s8.htm">March 24, 2021</a> (File No. 333-254654), <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036122007373/brhc10034627_s8.htm">March



















                  1, 2022</a> (File No. 333-263176), and <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036123010941/brhc10049419_s8.htm">March 9, 2023</a> (File No. 333-270430);</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z228ef02a27dc4c33afd18113c9bd971b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which included audited financial statements for the Registrant&#8217;s latest fiscal year, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1411690/000141169024000013/bngo-20231231.htm">March 5, 2024</a>;<br>
              </div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="e5f10ae4f8d841af84cc15aaea6f929b" class="DSPFListTable">

          <tr>
            <td style="width: 18pt;"></td>
            <td style="width: 18pt; vertical-align: top;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001411690/000141169024000021/bngo-20240331.htm">May 8, 2024</a>;</td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="e8bae0d53cb049b7b787aabc1a10920e" class="DSPFListTable">

          <tr>
            <td style="width: 18pt;"></td>
            <td style="width: 18pt; vertical-align: top;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">The Registrant's Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1411690/000114036124009930/ef20022651_8k.htm">February






                28, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1411690/000141169024000004/bngo-20240301.htm">March 5, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1411690/000114036124018181/ef20026117_8k.htm">April






                5, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1411690/000114036124018645/ny20026243x2_8k.htm">April 8, 2024</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001411690/000141169024000020/bngo-20240508.htm">May 8, 2024</a>; and</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zf08f221ee29149b0b49e4c425e9226eb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The description of the Registrant&#8217;s Common Stock contained in a registration statement on Form 8-A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518233217/d571624d8a12b.htm">July 31, 2018</a>
                (File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Exchange Act</font>&#8221;), including any amendment or report filed for the purpose of updating such
                description including <a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169024000013/bngo-ex45x20231231.htm">Exhibit 4.5</a> of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC
                on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1411690/000141169024000013/bngo-20231231.htm">March 5, 2024</a>.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;">All reports and other documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports or portions thereof
        furnished under Item 2.02 or Item 7.01 or any related Item 9.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into
        registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold
        or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a
        statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this
        registration statement, except as so modified or superseded.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zf31c7f35dbbf4f87ad12a3ce8504bc90" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-weight: bold;">Item 8.</div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="font-weight: bold;">&#160;Exhibits.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="za2202f0875744020b6dbb0d55d81f376" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 9.02%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Exhibit</div>
              <div style="font-weight: bold;">Number</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>4.1(1)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169023000082/bngo-2023x09x30xexx31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as amended.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>4.2(2)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">Amended and Restated Bylaws of the Registrant.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>4.3(3)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036123018454/brhc20051350_ex3-2.htm">Amendment to Amended and Restated Bylaws.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>4.4(4)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169024000013/bngo-ex41x20231231.htm">Form of Common Stock Certificate of the Registrant.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.1</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="ef20023291_ex5-1.htm">Opinion of Cooley LLP.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>23.1</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: top;">
              <div><a href="ef20023291_ex23-1.htm">Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>23.2</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="ef20023291_ex5-1.htm">Consent of Cooley LLP. Reference is made to Exhibit 5.1.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>24.1</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: top;">
              <div><a href="#POWEROFATTORNEY">Power of Attorney. Reference is made to the signature page hereto.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>99.1(5)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_ex99-1.htm">Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>99.1A(6)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: bottom;">
              <div style="font-size: 12pt;"><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169023000010/exh102a-bionanoxstandardfo.htm"><font style="font-size: 10pt;">Forms of grant notice, stock option agreement and notice of exercise
                    under the 2018 Plan.</font></a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>99.1B(7)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169023000010/exh102b-bionanoxdirectorfo.htm">Forms of director grant notice, stock option agreement and notice of exercise under the 2018 Plan.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>99.1C(8)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: bottom;">
              <div style="font-size: 12pt;"><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169023000010/exh102c-bionanoxdoublextri.htm"><font style="font-size: 10pt;">Forms of double-trigger grant notice, stock option agreement and notice
                    of exercise under the 2018 Plan.</font></a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>99.1D(9)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex105.htm">Forms of international grant notice, stock option agreement and notice of exercise under the 2018 Plan.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>99.1E(10)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: bottom;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169021000024/bngo-20210630xexx101.htm">Forms of restricted stock unit grant notice and restricted stock unit award agreement under the 2018 Plan.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>99.2(11)</div>
            </td>
            <td style="width: 1.54%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 89.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702dex995.htm">Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 9.02%; vertical-align: top;">
              <div>107</div>
            </td>
            <td style="width: 1.54%; vertical-align: top;">&#160;</td>
            <td style="width: 89.44%; vertical-align: top;">
              <div><a href="ef20023291_ex107.htm">Filing Fee Table.</a></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z0b58b350802447dbada89753a09ae97a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(1)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 8, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(2)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(3)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 14, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(4)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 5, 2024.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(5)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 99.1 of the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-245764), filed with the SEC on August 13, 2020.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(6)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 10.2A of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 9, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(7)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 10.2B of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 9, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(8)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 10.2C of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 9, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(9)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended, filed with the SEC on August 17, 2018.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(10)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 4, 2021.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.71%; vertical-align: top;">
              <div>(11)</div>
            </td>
            <td style="width: 94.29%; vertical-align: top;">
              <div>Incorporated by reference to Exhibit 99.5 of the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-227073), filed with the SEC on August 28, 2018.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
        caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 8, 2024.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z623b502b3d5b4ac88e5f2da4d3097c54" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-indent: -10pt; margin-left: 10pt; font-weight: bold;">BIONANO GENOMICS, INC.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-indent: -10pt; margin-left: 10pt;">/s/ R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt;">R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt; font-style: italic;">President and Chief Executive Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
      <div><br>
      </div>
      <div style="text-align: justify;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of R. Erik Holmlin, Ph.D. and G&#252;lsen Kama as his or her true and lawful attorney-in-fact and agent, with the
        full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits
        thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be
        done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to
        be done by virtue hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="za9b7d0d940074628956a125208b876e8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Signature</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Title</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">President, Chief Executive Officer and Director</div>
              <div style="text-align: center; font-style: italic;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: middle;">
              <div style="text-align: center;">R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ G&#252;lsen Kama</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Chief Financial Officer</div>
              <div style="text-align: center; font-style: italic;">(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">G&#252;lsen Kama</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ David L. Barker, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">David L. Barker, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Yvonne Linney, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Yvonne Linney, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Albert A. Luderer, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Albert A. Luderer, Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Hannah Mamuszka</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Hannah Mamuszka</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Aleksandar Rajkovic, M.D., Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Aleksandar Rajkovic, M.D., Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Christopher Twomey</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Christopher Twomey</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: top;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Kristiina Vuori, M.D., Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Kristiina Vuori, M.D., Ph.D.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Vincent Wong, J.D., M.B.A.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 39.08%; vertical-align: middle;" rowspan="2">
              <div style="text-align: center;">Director</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: normal;">May 8, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 39.08%; vertical-align: bottom;">
              <div style="text-align: center;">Vincent Wong, J.D., M.B.A.</div>
            </td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 20.45%; vertical-align: bottom; font-weight: normal;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <!-- base href="file:///C:/Users/kandikondav.BSG/AppData/Local/Temp/PROfile%20Green/zgwcyhlg.dyv/expand/content/ef20023291_s8.htm" -->
  <title></title>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ef20023291_s8.htm", "description": "S-8", "secsgml_size_bytes": 57679}]
{"company-data": {"conformed-name": "Bionano Genomics, Inc.", "cik": "0001411690", "assigned-sic": "3826", "organization-name": "08 Industrial Applications and Services", "irs-number": "261756290", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-279229", "film-number": "24927646"}, "business-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "(858) 888-7600"}, "mail-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "Bionano Genomics, Inc", "date-changed": "20190308"}, {"former-conformed-name": "BioNano Genomics, Inc", "date-changed": "20120703"}, {"former-conformed-name": "BioNanomatrix Inc", "date-changed": "20070906"}]}
As filed with the Securities and Exchange Commission on May 8, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Bionano Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
26-1756290
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
9540 Towne Centre Drive, Suite 100
San Diego, California
92121
(Address of Principal Executive Offices)
(Zip Code)
Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan
(Full titles of the plans)
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq.
Su Lian Lu, Esq.
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
(858) 550-6000
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large
        accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed by Bionano Genomics, Inc. (the "
Registrant
") with the Securities and Exchange Commission (the "
SEC
") for the purpose of registering (i) an additional 2,287,580 shares of Registrant's Common Stock, par value $0.0001 per share ("
Common
          Stock
"), issuable under the Registrant's 2018 Equity Incentive Plan, as amended (the "
2018 Plan
"), pursuant to the provisions of the 2018 Plan providing for an automatic increase
        on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan, and (ii) 22,000 additional shares of Common Stock issuable under the Registrant's 2018 Employee Stock Purchase Plan (the "
2018 ESPP
") pursuant to the provisions of the 2018 ESPP providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for
        issuance under the 2018 ESPP.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
These additional shares of Common Stock are securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the 2018 Plan and the 2018 ESPP are effective.
        The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 as noted below.
The following documents filed by the Registrant with the SEC
are incorporated by reference into this Registration Statement:
(a)
The contents of the earlier registration statements on Form S-8 filed with the SEC on
August 28, 2018
(File No. 333-227073),
March 29, 2019
(File No. 333-230589),
March 11,
                  2020
(File No. 333-237069),
August 14, 2020
(File No. 333-245764),
March 24, 2021
(File No. 333-254654),
March

                  1, 2022
(File No. 333-263176), and
March 9, 2023
(File No. 333-270430);
(b)
The Registrant's Annual Report on Form 10-K for the year ended December 31, 2023, which included audited financial statements for the Registrant's latest fiscal year, filed with the SEC on
March 5, 2024
;
(c)
The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on
May 8, 2024
;
(d)
The Registrant's Current Reports on Form 8-K filed with the SEC on
February

                28, 2024
,
March 5, 2024
,
April

                5, 2024
,
April 8, 2024
, and
May 8, 2024
; and
(e)
The description of the Registrant's Common Stock contained in a registration statement on Form 8-A filed with the SEC on
July 31, 2018
(File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the "
Exchange Act
"), including any amendment or report filed for the purpose of updating such
                description including
Exhibit 4.5
of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC
                on
March 5, 2024
.
All reports and other documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports or portions thereof
        furnished under Item 2.02 or Item 7.01 or any related Item 9.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into
        registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold
        or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents.
Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a
        statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this
        registration statement, except as so modified or superseded.
Item 8.
Exhibits.
Exhibit
Number
Description
4.1(1)
Amended and Restated Certificate of Incorporation of the Registrant, as amended.
4.2(2)
Amended and Restated Bylaws of the Registrant.
4.3(3)
Amendment to Amended and Restated Bylaws.
4.4(4)
Form of Common Stock Certificate of the Registrant.
5.1
Opinion of Cooley LLP.
23.1
Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.
23.2
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1
Power of Attorney. Reference is made to the signature page hereto.
99.1(5)
Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended.
99.1A(6)
Forms of grant notice, stock option agreement and notice of exercise
                    under the 2018 Plan.
99.1B(7)
Forms of director grant notice, stock option agreement and notice of exercise under the 2018 Plan.
99.1C(8)
Forms of double-trigger grant notice, stock option agreement and notice
                    of exercise under the 2018 Plan.
99.1D(9)
Forms of international grant notice, stock option agreement and notice of exercise under the 2018 Plan.
99.1E(10)
Forms of restricted stock unit grant notice and restricted stock unit award agreement under the 2018 Plan.
99.2(11)
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.
107
Filing Fee Table.
(1)
Incorporated by reference to Exhibit 3.1 of the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on November 8, 2023.
(2)
Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2018.
(3)
Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on April 14, 2023.
(4)
Incorporated by reference to Exhibit 4.1 of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 5, 2024.
(5)
Incorporated by reference to Exhibit 99.1 of the Registrant's Registration Statement on Form S-8 (File No. 333-245764), filed with the SEC on August 13, 2020.
(6)
Incorporated by reference to Exhibit 10.2A of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 9, 2023.
(7)
Incorporated by reference to Exhibit 10.2B of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 9, 2023.
(8)
Incorporated by reference to Exhibit 10.2C of the Registrant's Annual Report on Form 10-K, filed with the SEC on March 9, 2023.
(9)
Incorporated by reference to Exhibit 10.5 of the Registrant's Registration Statement on Form S-1 (File No. 333-225970), as amended, filed with the SEC on August 17, 2018.
(10)
Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on August 4, 2021.
(11)
Incorporated by reference to Exhibit 99.5 of the Registrant's Registration Statement on Form S-8 (File No. 333-227073), filed with the SEC on August 28, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
        caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 8, 2024.
BIONANO GENOMICS, INC.
By:
/s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of R. Erik Holmlin, Ph.D. and Gülsen Kama as his or her true and lawful attorney-in-fact and agent, with the
        full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits
        thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be
        done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to
        be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ R. Erik Holmlin, Ph.D.
President, Chief Executive Officer and Director
(Principal Executive Officer)
May 8, 2024
R. Erik Holmlin, Ph.D.
/s/ Gülsen Kama
Chief Financial Officer
(Principal Financial and Accounting Officer)
May 8, 2024
Gülsen Kama
/s/ David L. Barker, Ph.D.
Director
May 8, 2024
David L. Barker, Ph.D.
/s/ Yvonne Linney, Ph.D.
Director
May 8, 2024
Yvonne Linney, Ph.D.
/s/ Albert A. Luderer, Ph.D.
Director
May 8, 2024
Albert A. Luderer, Ph.D.
/s/ Hannah Mamuszka
Director
May 8, 2024
Hannah Mamuszka
/s/ Aleksandar Rajkovic, M.D., Ph.D.
Director
May 8, 2024
Aleksandar Rajkovic, M.D., Ph.D.
/s/ Christopher Twomey
Director
May 8, 2024
Christopher Twomey
/s/ Kristiina Vuori, M.D., Ph.D.
Director
May 8, 2024
Kristiina Vuori, M.D., Ph.D.
/s/ Vincent Wong, J.D., M.B.A.
Director
May 8, 2024
Vincent Wong, J.D., M.B.A.